Shares of Forty Seven, Inc. (FTSV) have traded between $5.54 – 45.4. The next earnings date is set for Mar 26, 2020. Let’s see how its prospects are shaping up.
What does Forty Seven, Inc.(FTSV) do?
Forty Seven, Inc. develops therapies that target cancer immune evasion pathways. It develops Hu5F9-G4, a monoclonal antibody against human CD47 that potentially has applications spanning multiple tumor types and treatment modalities. The company was founded by Irving L. Weissman, Ravi Majeti, Mark Chao and Jens-Peter Volkmer in 2014 and is headquartered in Menlo Park, CA.
FTSV Insider Trading Insight
On 2019-12-26, Weissman Irving Dir sold 30,000 shares of FTSV. That represents a value of $2,002,761. Not to be outdone, on 2019-12-16, Majeti Ravindra S – Sale sold25,000 shares of FTSV. These insiders are clearly in the know because they work closely with the company.
The CCC Consensus Price Target
The mean recommendation of Clarivate Analytics Plc from top Wall Street analysts is a Moderate Buy. That is based on 4 analysts who work on the Street. Based on 4 analysts offering 12 month price targets for Clarivate Analytics in the last 3 months. The average price target is $19.38 with a high forecast of $21.00 and a low forecast of $18.00. The average price target represents a 10.74% increase from the last price of $17.50. Last week, several articles were published in financial papers about CCC and 37% Bearish while 63% Bullish.